Researchers from KU Leuven presented novel urokinase plasminogen activator receptor-associated protein (uPARAP)-targeted ...

a Based on the 2003 Red Book average wholesale price of $538.42 per 250,000-IU vial and $0.17 and $0.05 per syringe and cap, respectively.

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid ...

the Company received regulatory clearance in Australia to commence a first-in-human Phase 1a therapeutic clinical trial of its novel urokinase plasminogen activator receptor (uPAR)-targeted ...